UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 6, 2011 (September 1, 2011)

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-16133 (Commission File Number)

06-1245881 (IRS Employer Identification Number)

810 Seventh Avenue, Suite 3505, New York, New York, 10019 (Address of principal executive offices, including zip code)

(212) 489-2100 (Registrant's telephone number, including area code)

NONE

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

C	•	0.1	`		,	
[]Written comm	unications purs	uant to Rule 425 t	under the Securitie	es Act (17 CFR 2	30.425)	
[]Soliciting mate	erial pursuant to	Rule 14a-12 und	er the Exchange A	act (17 CFR 240.	14a-12)	
[]Pre-commence	ement communi	cations pursuant t	to Rule 14d-2(b) u	nder the Exchan	ge Act (17 CFR 2	40.14d-2(b))

[]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On September 1, 2011, Delcath Systems, Inc. issued a press release announcing top-line results from the metastatic colorectal (adenocarcinoma) cohort of the Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibit

The following exhibit is filed herewith:

(d) Exhibits.

Exhibit No. Description

99.1 Press Release of Delcath Systems, Inc., dated September 1, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELCATH SYSTEMS, INC.

Dated: September 6, 2011 By: /s/ Peter J. Graham

Name: Peter J. Graham

Title: Executive Vice President, General

Counsel

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release of Delcath Systems, Inc., dated September 1, 2011